Inhaler user preference study in COPD patients

  • Research type

    Research Study

  • Full title

    Study 200301: An open-label study of inhaler device attributes investigating critical and overall errors, ease of use, and preference between a number of inhaler devices (ELLIPTA, TURBUHALER, HANDIHALER, BREEZHALER, MDI, and DISKUS/ACCUHALER) in adult subjects with Chronic Obstructive Pulmonary Disease (COPD)

  • IRAS ID

    161349

  • Contact name

    Michael Thomas

  • Contact email

    D.M.Thomas@soton.ac.uk

  • Sponsor organisation

    GlaxoSmithKline UK Pharma

  • Research summary

    This study will assess the number of errors made by subjects when using the ELLIPTA inhaler device and one of the other inhaler devices, neither of which have been used by the subject before (i.e., DISKUS, TURBUHALER, HANDIHALER, BREEZHALER and MDI). In addition, ease of use and preference of the inhaler devices will be assessed.
    During this single visit study, subjects with COPD, will be allocated to one of five groups and receive the ELLIPTA device and one other device. All the inhaler devices in this study will contain placebo only. Subjects will be able to continue their current COPD and other medications during this study. Baseline assessments will include height, weight, ethnic origin, medical/disease history including family history, COPD history, any additional existing conditions, current health and literacy/reading ability score. Adverse events will be recorded.
    Once randomised, subjects will receive either the ELLIPTA device first or one of the other devices. The subjects will be asked to read the patient instruction leaflet then to use it. The number of errors they make during the use of the inhaler device will be recorded. If errors are made, the Healthcare Professional (HCP) will demonstrate the correct use of the inhaler to the subject. The subject will then be asked to demonstrate inhaler use again. Any errors from this attempt will be recorded. In total, the HCP will demonstrate the use of the inhaler up to three times. After completing the process with the first inhaler, the same procedures will be followed for the second inhaler. The time taken to complete the demonstration steps will be recorded.
    Afterwards the HCP will ask the subject a number of questions from two questionnaires. One questionnaire will be based on the ‘ease of use’ of the device and the other related to preference.

  • REC name

    West of Scotland REC 4

  • REC reference

    14/WS/1055

  • Date of REC Opinion

    11 Sep 2014

  • REC opinion

    Further Information Favourable Opinion